广州中医药大学学报2026，Vol.43Issue(3)：589-595,7.DOI:10.13359/j.cnki.gzxbtcm.2026.03.006
加味柴胡桂枝汤联合氟哌噻吨美利曲辛对脑卒中伴抑郁-焦虑患者负性心理、睡眠及血清HDAC3、Beclin-1的影响
Effects of Modified Chaihu Guizhi Decoction Combined with Flupentixol and Melitracen on Negative Psychological State,Sleep,and Serum Levels of HDAC3 and Beclin-1 in Stroke Patients with Depression-Anxiety
摘要
Abstract
Objective To investigate the effects of Modified Chaihu Guizhi Decoction combined with flupentixol and melitracen on negative psychological state,sleep,and serum levels of histone deacetylase 3(HDAC3)and Bcl-2 interacting protein 1(Beclin-1)in stroke patients with depression-anxiety.Methods A total of 126 stroke patients with depression-anxiety of liver qi stagnation syndrome admitted to Pingdingshan Second People's Hospital from January 2023 to January 2025 were selected as the studying subjects.Patients were randomly divided into a conventional group and an trial group using a random number table,with 63 patients in each group.Both groups received conventional treatment for cerebrovascular disease.The conventional group additionally received Flupentixol and Melitracen,while the trial group received Modified Chaihu Guizhi Decoction in combination with Flupentixol and Melitracen.The treatment course for both groups was 6 weeks.Changes in neurological function assessed by the National Institutes of Health Stroke Scale(NIHSS)score,Hamilton Depression Rating Scale(HAMD)score,Hamilton Anxiety Rating Scale(HAMA)score,Pittsburgh Sleep Quality Index(PSQI)score,and serum levels of HDAC3 and Beclin-1 were observed before and after treatment.The safety of the two treatment regimens was also evaluated.Results(1)There were 5 cases dropped out from the conventional group and 4 from the trial group during the study,resulting in 58 cases in the conventional group and 59 cases in the trial group completing the full treatment course.(2)In terms of neurological function,after 6 weeks of treatment,the NIHSS scores decreased in both groups compared to those before treatment(P＜0.05),and the reduction was significantly greater in the trial group than in the conventional group(P＜0.01).(3)Regarding depression and anxiety states,after 6 weeks,the HAMD and HAMA scores decreased in both groups compared to those before treatment(P＜0.05),and the reductions were significantly greater in the trial group than in the conventional group(P＜0.01).(4)Regarding sleep quality,after 6 weeks,the PSQI scores decreased in both groups compared to those before treatment(P＜0.05),and the reduction was significantly greater in the trial group than in the conventional group(P＜0.01).(5)Regarding serological indicators,after 6 weeks,serum HDAC3 levels decreased in both groups compared to those before treatment(P＜0.05),while serum Beclin-1 levels increased(P＜0.05);the reduction in serum HDAC3 and the increase in serum Beclin-1 were both significantly greater in the trial group than in the conventional group(P＜0.01).(6)Regarding safety,the incidence of adverse reactions during treatment was 6.78%(4/59)in the trial group and 13.79%(8/58)in the conventional group,with no statistically significant difference between the groups(P＞0.05).Conclusion Modified Chaihu Guizhi Decoction combined with Flupentixol and Melitracen can effectively improve serum levels of HDAC3 and Beclin-1,reduce the degree of neurological deficit and negative psychological state,and enhance sleep quality in stroke patients with depression-anxiety of liver qi stagnation syndrome,without increasing adverse reactions,demonstrating a favorable safety profile.关键词
脑卒中/抑郁-焦虑/肝气郁结型/氟哌噻吨美利曲辛/加味柴胡桂枝汤/负性心理/睡眠质量/组蛋白去乙酰化酶3/Bcl-2相互作用蛋白1Key words
stroke/depression-anxiety/liver qi stagnation syndrome/Flupentixol and Melitracen/Modified Chaihu Guizhi Decoction/negative psychological state/sleep quality/histone deacetylase 3/Bcl-2 interacting protein 1分类
医药卫生引用本文复制引用
范晓歌,张敏,王小亚..加味柴胡桂枝汤联合氟哌噻吨美利曲辛对脑卒中伴抑郁-焦虑患者负性心理、睡眠及血清HDAC3、Beclin-1的影响[J].广州中医药大学学报,2026,43(3):589-595,7.基金项目
国家重点研发计划项目(编号:2022YFC2502400) （编号:2022YFC2502400）
